For a long time, Roche’s three drugs, Rituxan, Herceptin and Avastin, dominated the global market.
However, on July 18, their competitors appeared – Amgen and Allergan introduced the biosimilars of Herceptin preparations for the treatment of HER2-positive breast cancer and Avastin for the treatment of colorectal cancer to the USA, which threatened the total sales volume of two originators produced in 2018.
Mvasi, Avastin’s biosimilar from Amgen, became the first biosimilar of the drug, which was approved by the FDA at the end of 2017. The American regulator approved Kanjinti, Herceptin’s biosimilar, in June of this year.
These biosimilars will enter the market at a wholesale price that is 15% lower than the price of
reference biotech drugs.
For Amgen and Allergan, the departure from Roche’s “settlement” will help get more dividends in terms of sales, while for other competitors the outlook may be bleak.
Rituxan, whose sales in the US in 2018 amounted to $4.24 billion, could be hit by the following biosimilars.